Skip to main content
SpringerLink
Log in

RANK-Ligand-Hemmung in der Therapie der Osteoporose

  • Chapter
Fortbildung Osteologie

Part of the book series: Fortbildung Osteologie ((FORTOSTEO,volume 3))

  • 1468 Accesses

Zusammenfassung

Die klinisch relevanten, häufigsten Osteoporoseformen entstehen aufgrund einer exzessiv gesteigerten osteoklastären Knochenresorption. Hierfür kann es verschiedene Ursachen geben. Mögliche Störungen können in der Entstehung (Osteoklastendifferenzierung aus den Vorläuferzellen) und in der Aktivität (Fusionsstörung, Hemmung der Apoptoseinduktion) der Osteoklasten auftreten. Das RANK/RANKL/OPG-System ist in seiner Intaktheit für ein ausgeglichenes „bone remodeling“ verantwortlich und damit der Garant einer stabilen Knochenstruktur.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 74.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  1. Bekker PJ et al. (2004) A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women. J Bone Miner Res 19: 1059–1066

    Article  CAS  PubMed  Google Scholar 

  2. Bone HG et al. (2008) Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women. J Clin Endocrin Metab 93: 2149–2157

    Article  CAS  Google Scholar 

  3. Brown JP et al. (2009) Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial. J Bone Miner Res 24: 153–161

    Article  CAS  PubMed  Google Scholar 

  4. Cummings SR et al. (2009) Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. N Engl J Med 361: 756–765

    Article  CAS  PubMed  Google Scholar 

  5. Kendler DL et al. (2009) Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women Transitioning from Alendronate Therapy. J Bone Miner Res epub, doi: 10.1359/jbmr.090716

    Google Scholar 

  6. Lewiecki EM et al. (2007) Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD. J Bone Miner Res; 22:1832–1841

    Article  CAS  PubMed  Google Scholar 

  7. McClung MR et al. (2006) Denosumab in Postmenopausal Women with Low Bone Mineral Density. New Engl J Med 354: 821–831

    Article  CAS  PubMed  Google Scholar 

  8. Miller PD et al. (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone 43: 222–229

    Article  CAS  PubMed  Google Scholar 

  9. Penning-can Beest FJA et al. (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19: 511–517

    Article  Google Scholar 

  10. S3-Leitlinien des Dachverbandes Osteologie (DVO) zur Diagnostik und Therapie der Osteoporose (2009) http://www.dv-osteologie. org/dvo_leitlinien/dvo-leitlinie-2009. Gesehen Jan. 2010

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Unfall- und Handchirurgie, Universitätsklinikum Düsseldorf, Moorenstraße 5, D-40225, Düsseldorf

    Dr. med. Ulla Stumpf

  2. Abteilung für Innere Medizin, Hospital zum Heiligen Geist, Von-Broichhausen-Allee 1, D-47906, Kempen

    Prof. Dr. med. Walter Josef Fassbender

Authors
  1. Dr. med. Ulla Stumpf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Walter Josef Fassbender
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Stumpf, U., Fassbender, W.J. (2010). RANK-Ligand-Hemmung in der Therapie der Osteoporose. In: Fortbildung Osteologie. Fortbildung Osteologie, vol 3. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-05385-6_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-05385-6_27

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-05384-9

  • Online ISBN: 978-3-642-05385-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation